Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

FOXA1 in breast cancer

View through CrossRef
Breast cancer is a heterogeneous disease and classification is important for clinical management. At least five subtypes can be identified based on unique gene expression patterns; this subtype classification is distinct from the histopathological classification. The transcription factor network(s) required for the specific gene expression signature in each of these subtypes is currently being elucidated. The transcription factor network composed of the oestrogen (estrogen) receptor α (ERα), FOXA1 and GATA3 may control the gene expression pattern in luminal subtype A breast cancers. Breast cancers that are dependent on this network correspond to well-differentiated and hormone-therapy-responsive tumours with good prognosis. In this review, we discuss the interplay between these transcription factors with a particular emphasis on FOXA1 structure and function, and its ability to control ERα function. Additionally, we discuss modulators of FOXA1 function, ERα–FOXA1–GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1.
Title: FOXA1 in breast cancer
Description:
Breast cancer is a heterogeneous disease and classification is important for clinical management.
At least five subtypes can be identified based on unique gene expression patterns; this subtype classification is distinct from the histopathological classification.
The transcription factor network(s) required for the specific gene expression signature in each of these subtypes is currently being elucidated.
The transcription factor network composed of the oestrogen (estrogen) receptor α (ERα), FOXA1 and GATA3 may control the gene expression pattern in luminal subtype A breast cancers.
Breast cancers that are dependent on this network correspond to well-differentiated and hormone-therapy-responsive tumours with good prognosis.
In this review, we discuss the interplay between these transcription factors with a particular emphasis on FOXA1 structure and function, and its ability to control ERα function.
Additionally, we discuss modulators of FOXA1 function, ERα–FOXA1–GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1.

Related Results

Abstract 7763: FOXA1 in ovarian cancer: Therapeutic target and immunotherapy enhancer
Abstract 7763: FOXA1 in ovarian cancer: Therapeutic target and immunotherapy enhancer
Abstract OBJECTIVE This study aimed to elucidate the oncogenic role of FOXA1 (Forkhead Box A1) in ovarian cancer and to e...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract Neuroendocrine prostate cancer (NEPC) is a subtype of prostate cancer that is highly aggressive and exhibits a neuroendocrine phenotype, being distinct from...
Abstract 1331: A novel approach to treating hormonal breast cancer using clinical database and 3D ex vivo model
Abstract 1331: A novel approach to treating hormonal breast cancer using clinical database and 3D ex vivo model
Abstract Type 2 diabetes (T2D) female patients have a higher risk of being diagnosed and have worse survival for breast cancer compared to non-diabetic females. Alth...
Abstract 1976: Androgen receptor activity is reprogrammed by lysine-specific demethylase 1 in prostate cancer
Abstract 1976: Androgen receptor activity is reprogrammed by lysine-specific demethylase 1 in prostate cancer
Abstract In the recurrent PCa treated with CYP17A1 inhibitor (abiraterone) and more potent AR antagonist (enzalutamide), high levels of AR and AR regulated genes ind...
Abstract 1464: Zaniya Mark
Abstract 1464: Zaniya Mark
Abstract Prostate cancer (PCa) is one of the most common types of cancers diagnosed in American men. Moreover, PCa malignancy disproportionally strikes more on Afric...

Back to Top